Curated News
By: NewsRamp Editorial Staff
April 14, 2025
Biotech Firm Immunic Closes Direct Stock Offering, Raises $5.1M
TLDR
- Investors can benefit from Immunic's registered direct offering of common stock at $0.90 per share, led by Aberdeen Investments.
- Immunic, a biotech company, closed a direct stock offering, raising $5.1 million to fund clinical trials and operations for chronic inflammatory and autoimmune diseases.
- Immunic's development of small molecule therapies for chronic diseases aims to improve patient outcomes and quality of life.
- IMU-838's therapeutic activity in multiple sclerosis and ulcerative colitis shows promise for treating various autoimmune and inflammatory conditions.
Impact - Why it Matters
This news matters as it showcases Immunic's successful fundraising efforts to support its pipeline of therapies for chronic inflammatory and autoimmune diseases. The company's progress in securing funding highlights its commitment to advancing treatments for these debilitating conditions.
Summary
Immunic (NASDAQ: IMUX), a biotechnology company, has closed a direct offering of its common stock, raising $5.1 million to fund clinical trials and operations. Led by Aberdeen Investments, the offering included 5,666,667 shares priced at $0.90 each. Titan Partners Group acted as the sole placement agent for the transaction.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Biotech Firm Immunic Closes Direct Stock Offering, Raises $5.1M
